Search academic texts

Information × Registration Number 0215U004031, 0112U002129 , R & D reports Title Elaborate the complex of diagnostic and treatment measures in order to prevent progressive chronic hepatitis B and C in children popup.stage_title Head Denysova Margaryta; Tshypkun Anatoliy, Registration Date 29-01-2015 Organization State organization "Institute of pediatrics, obstetrics and gynecology NAMS of Ukraine" popup.description2 Research is devoted to solving the problem of improving the diagnosis and treatment of chronic viral hepatitis B and C in children in remission. Based on a retrospective analysis of 100 case histories of children with chronic viral hepatitis B and C in remission for the first time shown that 40% of patients with chronic viral hepatitis-B and in 37% of patients with chronic viral hepatitis C in remission retained activity of the inflammatory process, identifies markers of disease progression that possible to identify at risk for the formation of an unfavorable course of chronic viral hepatitis and the likelihood of developing cirrhosis. Surprisingly, the progressive course of chronic viral hepatitis in remission may be caused not only by the presence of minimal inflammatory activity, but also the depletion of the regeneration system, as evidenced by data from a study of one of the markers of the regenerative capacity of the liver - hepatocyte growth factor. It is proved that for chronic viral hepatitis in remission accompanied by manifestations of oxidative stress, which is one of the most powerful inducers of hepatic fibrosis. First proved the feasibility and exponential use of modern non-invasive methods - ultrasonic remote palpation (elastography) and multidetector computed tomography, which is already in the early stages can detect hemodynamic disturbances and fibrotic changes in the liver parenchyma. In order to improve anti-treatment schemes chronic viral hepatitis in remission developed treatments and preventive measures, the effect of which is aimed at eliminating oxidative stress, inhibition of fibrogenesis, hemodynamic recovery. Reasonably prolonged period of its use - 6 months. The detection rate of indirect serological markers of liver fibrosis in patients treated with anti-treatment 6 months decreased by 25%; within 3 months - 12%. Relapse rate at follow-up was 2.5 times lower. Product Description popup.authors Диба М.Б. Дикан І.І. Музика Н.М. Поліщук О.І. Чернега Н.В. popup.nrat_date 2020-04-02 Close